Means for inhibiting the expression of protein kinase 3

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 9/12 (2006.01) C12N 15/11 (2006.01)

Patent

CA 2658550

The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ.ID.No. 1 (NM_013355), or part thereof whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 482 to 500 of SEQ. ID.No. 1 (SEQ. ID.No. 2); from nucleotide positions 1555 to 1573 of SEQ. ID.No. 1 (SEQ.ID.No. 4); from nucleotide positions 1556 to 1574 of SEQ. ID.No. 1 (SEQ.ID.No. 6); from nucleotide positions 1559 to 1577 of SEQ. ID.No. 1 (SEQ.ID.No. 8); from nucleotide positions 1566 to 1584 of SEQ. ID.No. 1 (SEQ.ID.No. 10); from nucleotide positions 2094 to 2112 of SEQ. ID.No. 1 (SEQ.ID.No. 12); from nucleotide positions 2102 to 2120 of SEQ. ID.No. 1 (SEQ.ID.No. 14); from nucleotide positions 2286 to 2304 of SEQ. ID.No. 1 (SEQ.ID.No. 16); from nucleotide positions 2761 to 2779 of SEQ. ID.No. 1 (SEQ.ID.No. 18); from nucleotide positions 2763 to 2781 of SEQ. ID.No. 1 (SEQ.ID.No. 20); from nucleotide positions 2764 to 2782 of SEQ. ID.No. 1 (SEQ.ID.No. 22); from nucleotide positions 2843 to 2861 of SEQ. ID.No. 1 (SEQ.ID.No. 24); from nucleotide positions 2844 to 2862 of SEQ. ID.No. 1 (SEQ.ID.No. 26); or from nucleotide positions 2846 to 2864 of SEQ. ID.No. 1 (SEQ.ID.No. 28), preferably the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1555 to 1573 of SEQ. ID.No. 1 (SEQ.ID.No. 4); from nucleotide positions 1556 to 1574 of SEQ. ID.No. 1 (SEQ.ID.No. 6); from nucleotide positions 1559 to 1577 of SEQ. ID.No. 1 (SEQ.ID.No. 8); from nucleotide positions 1566 to 1584 of SEQ. ID.No. 1 (SEQ.ID.No. 10); from nucleotide positions 2094 to 2112 of SEQ. ID.No. 1 (SEQ.ID.No. 12); or from nucleotide positions 2286 to 2304 of SEQ. ID.No. 1 (SEQ.ID.No. 16), whereby preferably the first stretch is additionally at least partially complementary to a region preceding the 5' end of the nucleotide core sequence and/or to a region following the 3' end of the nucleotide core sequence.

La présente invention concerne une molécule d'acide nucléique comprenant une structure bicaténaire, la structure bicaténaire comprenant un premier brin et un second brin, le premier brin comprenant une première suite de nucléotides contigus et ladite première suite étant au moins partiellement complémentaire d'un acide nucléique cible, et le second brin comprenant une seconde suite de nucléotides contigus et ladite seconde suite étant au moins partiellement complémentaire de la première suite, la première suite comprenant une séquence d'acides nucléiques qui est au moins partiellement complémentaire d'une séquence nucléotidique de base de la séquence d'acides nucléiques selon SEQ.ID.No. 1 (NM_013355), ou d'une partie de celle-ci, la séquence nucléotidique de base comprenant la séquence nucléotidique s'étendant des positions nucléotidiques 482 à 500 de SEQ. ID.No. 1 (SEQ. ID.No. 2); des positions nucléotidiques 1555 à 1573 de SEQ. ID.No. 1 (SEQ.ID.No. 4); des positions nucléotidiques 1556 à 1574 de SEQ. ID.No. 1 (SEQ.ID.No. 6); des positions nucléotidiques 1559 à 1577 de SEQ. ID.No. 1 (SEQ.ID.No. 8); des positions nucléotidiques 1566 à 1584 de SEQ. ID.No. 1 (SEQ.ID.No. 10); des positions nucléotidiques 2094 à 2112 de SEQ. ID.No. 1 (SEQ.ID.No. 12); des positions nucléotidiques 2102 à 2120 de SEQ. ID.No. 1 (SEQ.ID.No. 14); des positions nucléotidiques 2286 à 2304 de SEQ. ID.No. 1 (SEQ.ID.No. 16); des positions nucléotidiques 2761 à 2779 de SEQ. ID.No. 1 (SEQ.ID.No. 18); des positions nucléotidiques 2763 à 2781 de SEQ. ID.No. 1 (SEQ.ID.No. 20); des positions nucléotidiques 2764 à 2782 de SEQ. ID.No. 1 (SEQ.ID.No. 22); des positions nucléotidiques 2843 à 2861 de SEQ. ID.No. 1 (SEQ.ID.No. 24); des positions nucléotidiques 2844 à 2862 de SEQ. ID.No. 1 (SEQ.ID.No. 26); ou des positions nucléotidiques 2846 à 2864 de SEQ. ID.No. 1 (SEQ.ID.No. 28), de préférence la séquence nucléotidique de base comprenant la séquence nucléotidique s'étendant des positions nucléotidiques 1555 à 1573 de SEQ. ID.No. 1 (SEQ.ID.No. 4); des positions nucléotidiques 1556 à 1574 de SEQ. ID.No. 1 (SEQ.ID.No. 6); des positions nucléotidiques 1559 à 1577 de SEQ. ID.No. 1 (SEQ.ID.No. 8); des positions nucléotidiques 1566 à 1584 de SEQ. ID.No. 1 (SEQ.ID.No. 10); des positions nucléotidiques 2094 à 2112 de SEQ. ID.No. 1 (SEQ.ID.No. 12); ou des positions nucléotidiques 2286 à 2304 de SEQ. ID.No. 1 (SEQ.ID.No. 16), de préférence la première suite étant également au moins partiellement complémentaire d'une région précédant l'extrémité 5' de la séquence nucléotidique de base et/ou d'une région suivant l'extrémité 3' de la séquence nucléotidique de base.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Means for inhibiting the expression of protein kinase 3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Means for inhibiting the expression of protein kinase 3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means for inhibiting the expression of protein kinase 3 will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2078582

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.